These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 22265953)

  • 1. [Renal disease in ANCA-associated vasculitis].
    Vanhille P; Vrigneaud L; Quéméneur T
    Presse Med; 2012 Mar; 41(3 Pt 1):247-53. PubMed ID: 22265953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
    Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
    Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
    Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
    J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of rituximab trials on the treatment of ANCA-associated vasculitis.
    Alberici F; Jayne DR
    Nephrol Dial Transplant; 2014 Jun; 29(6):1151-9. PubMed ID: 24126571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.
    Jones RB
    Nephron Clin Pract; 2014; 128(3-4):243-9. PubMed ID: 25401382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
    Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
    Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ANCA positive crescentic glomerulonephritis outcome in a Central East European cohort: a retrospective study.
    Andreiana I; Stancu S; Avram A; Taran L; Mircescu G
    BMC Nephrol; 2015 Jun; 16():90. PubMed ID: 26123651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of ANCA-associated vasculitis: new therapies and a look at old entities.
    Zand L; Specks U; Sethi S; Fervenza FC
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):182-93. PubMed ID: 24602467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy and prognosis of ANCA-associated vasculitis from the clinical nephrologist's perspective.
    Haris Á; Dolgos S; Polner K
    Int Urol Nephrol; 2017 Jan; 49(1):91-102. PubMed ID: 27671907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S2. Rituximab for ANCA-associated vasculitis: the UK experience.
    Jayne D
    Presse Med; 2013 Apr; 42(4 Pt 2):532-4. PubMed ID: 23490639
    [No Abstract]   [Full Text] [Related]  

  • 11. ANCA-associated vasculitis in scleroderma: A renal perspective
.
    Kant S; Shah AA; Hummers LK; Wigley FM; Geetha D
    Clin Nephrol; 2018 Dec; 90(6):413-418. PubMed ID: 30106367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides.
    Charles P; Bienvenu B; Bonnotte B; Gobert P; Godmer P; Hachulla É; Hamidou M; Harlé JR; Karras A; Lega JC; Le Quellec A; Mahr AD; Mouthon L; Papo T; Puéchal X; Pugnet G; Samson M; Sibilia J; Terrier B; Vandergheynst F; Guillevin L;
    Presse Med; 2013 Oct; 42(10):1317-30. PubMed ID: 24095054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis.
    Kallenberg CG; Hauser T
    Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1():i119-22. PubMed ID: 25753806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal Involvement in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Zonozi R; Niles JL; Cortazar FB
    Rheum Dis Clin North Am; 2018 Nov; 44(4):525-543. PubMed ID: 30274621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rituximab for the treatment of ANCA associated vasculitis: the future today?].
    Alba MA; Flores-Suárez LF
    Reumatol Clin; 2011 Dec; 7 Suppl 3():S41-6. PubMed ID: 22115869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?
    Tesar V; Hruskova Z
    Expert Opin Pharmacother; 2015; 16(11):1683-702. PubMed ID: 26149512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis.
    Rutgers A; Kallenberg CG
    Curr Opin Rheumatol; 2012 May; 24(3):245-51. PubMed ID: 22410545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the treatment of ANCA associated vasculitis.
    Smith RM
    Presse Med; 2015 Jun; 44(6 Pt 2):e241-9. PubMed ID: 26021670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for remission induction in recurrent ANCA-associated glomerulonephritis postkidney transplant.
    Murakami C; Manoharan P; Carter-Monroe N; Geetha D
    Transpl Int; 2013 Dec; 26(12):1225-31. PubMed ID: 24118474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
    Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
    N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.